Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P78325
UPID:
ADAM8_HUMAN
Alternative names:
Cell surface antigen MS2
Alternative UPACC:
P78325; B4DVM6; H0YL36; H0YLR0; H0YN39
Background:
Disintegrin and metalloproteinase domain-containing protein 8, also known as Cell surface antigen MS2, plays a crucial role in the immune response, particularly in the extravasation of leukocytes. This process is vital for the immune system's ability to respond to injury and infection.
Therapeutic significance:
Understanding the role of Disintegrin and metalloproteinase domain-containing protein 8 could open doors to potential therapeutic strategies. Its involvement in leukocyte extravasation suggests it may be a target for modulating immune responses in various diseases.